Maddi Hebebrand, MC, Associate Editor

Despite high accuracy scores, the study found AI models often produce overly complex explanations, making them less effective for patient education.

The trial revealed that 40% of patients on izokibep achieved HiSCR75 by week 16, a notable improvement over the 20% on placebo.

Researchers suggested that itch control is key in reducing disease burden and improving life quality for patients with psoriasis and atopic dermatitis.

The study found 277 differentially expressed genes shared by RA and rosacea, opening up opportunities for treatment research.

A recent Australian study reviewed appropriate terminology, gender affirming options, and dermatological considerations in caring for gender-diverse patients.

Researchers linked higher exposure to natural environments and green spaces with an increased risk of developing psoriasis.

Researchers emphasized the need for improved reliability and regulatory frameworks for AI tools before they are integrated into dermatological practice.

Follow-up results showed that 6 out of 9 patients achieved HiSCR at 3 months, with 5 maintaining this response at 6 months.

Both 8-week and 16-week dosing intervals of guselkumab achieved similar clinical outcomes and patient-reported responses in the GUIDE trial.

A group of international experts focused on the technology’s potential to standardize and enhance patient assessments.

The 15-piece questionnaire is designed to be quick and easy to use during consultations, with particular benefits across numerous specialties.

A recent study revealed that CO2 fractional laser was significantly more effective than microneedling for acne treatment with ALA-PDT.

Participants experienced improvements with both glove types, though cotton gloves were generally preferred for comfort and Sympatex for tactile sensitivity.

A review of 43 studies found that systemic treatments generally provide greater reductions in rosacea ILs compared to topical therapies.

Researchers suggested that early intervention with less than 2 years of disease duration was associated with a lower risk of relapse.

Researchers stated the drug could avoid the need for additional immunosuppressive treatments associated with increased morbidity and mortality.

PIH, more prominent in darker skin types, often leads to significant psychosocial distress and reduced quality of life.

A recent review called for gender-specific studies to enhance dermatological treatments and potentially revise guidelines.

Researchers noted how historical bias in dermatology research has impacted the understanding and treatment of conditions in darker skin.

A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how the publication has impacted their practice.

The study highlights the need for personalized treatments, suggesting that this combination therapy is most beneficial when tailored to individual risk profiles.

Researchers behind the phase 3 studies gave pearls into the study methods, results, and what is up next.

A recent study saw a “significant” decrease in allergen-specific IgE levels over a 1-year period of dupilumab therapy in children with atopic dermatitis.

A recent review investigated all known information between skin conditions and sleep disorders, finding a bidirectional influence between them.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on key career mentors.

Robert Posnick, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving hyperpigmentation and alopecia areata.

The study saw a reduction of 2 major UVA-induced mtDNA deletions associated with skin photoaging.

A recent study found that pharmacy professionals had an increased level of capability, opportunity, and motivation after accessing the resource.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on how patient interactions have changed over time.